Trial ID or NCT#

NCT03132636

Status

RECRUITING

Purpose

The primary objective is to estimate the overall response rate (ORR) for metastatic Basal Cell Carcinoma (BCC) (group 1) and for unresectable locally advanced BCC (group 2) when treated with REGN2810 as a monotherapy

Official Title

A Phase 2 Study of REGN2810, a Fully Human Monoclonal Antibody to Programmed Death-1, in Patients With Advanced Basal Cell Carcinoma Who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy, or Were Intolerant of Prior Hedgehog Pathway Inhibitor Therapy

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No

Investigator(s)

Anne Lynn S. Chang, MD
Dermatologist, General dermatologist, Dermatologic oncologist, Cutaneous oncology specialist
Associate Professor of Dermatology at the Stanford University Medical Center

Contact us to find out if this trial is right for you.

CONTACT

Alexander Ayon Valencia
(650) 498-5185